Skip to content
All news
Analysis

Merck (MRK) Stock Looks Like A Bargain At This Price

A Discounted Cash Flow (DCF) analysis of Merck (MRK) points to meaningful upside relative to the current share price of $123.54, following a cumulative return of 87.4% over the past five years. However, broader valuation metrics present a more mixed picture.

July 13, 2026
2 min read
Source: Simply Wall St.
Share:

Key Numbers

5 year return
87.4%
current price
123.54
upside potential
meaningful

According to an analysis by Simply Wall St, Merck & Co. (MRK) appears undervalued at current levels.

Recommendation Change

No specific analyst has issued a new recommendation, but a Discounted Cash Flow (DCF) analysis suggests upside potential compared to the current stock price of $123.54.

Analyst Rationale

The analysis is based on a DCF model that estimates the fair value of the stock based on expected future cash flows. The model indicates that the stock may be undervalued, especially as Merck continues to expand its Keytruda and broader oncology pipeline.

Context

Over the past five years, Merck stock has delivered an 87.4% total return, raising the question for new buyers of whether that past compounding already reflects much of the company's progress. Other valuation metrics present a mixed picture, with not all indicators aligning with the upside suggested by the DCF.

What We Conclude

While the DCF analysis points to a potential buying opportunity, investors should consider the broader valuation landscape and the company's future performance before making any decisions.

Frequently Asked Questions

Discounted Cash Flow (DCF) analysis is a valuation method that estimates the fair value of an investment based on its expected future cash flows, discounted to their present value.

Found this useful? Share it

Share:
This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.